{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:30:58Z","timestamp":1788345058880,"version":"build-2803163510"},"reference-count":30,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Sex Reprod Health"],"accepted":{"date-parts":[[2019,10,30]]},"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>There is unmet need for male contraceptive options, but a recent injectable combination male contraceptive trial was terminated early due to adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We examined the frequency of reported AEs by male research participants compared with AEs reported in prescribing information of approved female hormonal contraceptive methods. Published data from trials of the top five most-used female hormonal contraceptives, supplemented by contemporary contraceptive research, were compared with the frequency of AEs reported in a male injectable hormonal contraceptive trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We observed similar frequencies of AEs reported by users of male contraceptives compared with those reported by female users. Among quantitatively comparable AEs, compared with men, women reported experiencing higher frequencies of headaches, pelvic pain, and weight gain and similar frequencies of decreased libido. Compared with women, men reported experiencing higher frequencies of acne and mood changes. Men discontinued participation due to AEs at a lower frequency than women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Female hormonal methods generally have similar frequencies of AEs to those reported in a recent male hormonal contraceptive trial, and male users had lower rates of discontinuation due to AEs. There were fewer serious AEs of the male contraceptive than reported in contemporary female trials which resulted in FDA licensure. This suggests there may be implicit bias in the scientific community regarding the level of acceptable risk for users of male contraceptive methods.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjsrh-2018-200206","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T17:24:23Z","timestamp":1574357063000},"page":"139-146","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Assessing safety in hormonal male contraception: a critical appraisal of adverse events reported in a male contraceptive trial"],"prefix":"10.1136","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9050-2175","authenticated-orcid":false,"given":"Carmen","family":"Abbe","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington, USA"},{"name":"Scripps College, Claremont, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison C","family":"Roxby","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington, USA"},{"name":"Department of Global Health, University of Washington, Seattle, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"key":"2025090510305356000_46.2.139.1","doi-asserted-by":"publisher","DOI":"10.1363\/psrh.12017"},{"key":"2025090510305356000_46.2.139.2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2164\/jandrol.106.002311","article-title":"10th Summit Meeting consensus: recommendations for regulatory approval for hormonal male contraception","volume":"28","author":"Aaltonen","year":"2006","journal-title":"J Androl"},{"key":"2025090510305356000_46.2.139.3","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92416-F"},{"key":"2025090510305356000_46.2.139.4","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0069"},{"key":"2025090510305356000_46.2.139.5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030107"},{"key":"2025090510305356000_46.2.139.6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2604"},{"key":"2025090510305356000_46.2.139.7","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dei300"},{"key":"2025090510305356000_46.2.139.8","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1210\/jc.2016-2141","article-title":"Efficacy and safety of an injectable combination hormonal contraceptive for men","volume":"101","author":"Behre","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2025090510305356000_46.2.139.9","unstructured":"Daniels K , Mosher WD , Jones J . Contraceptive methods women have ever used: United States, 1982\u20132010. Natl Health Stat Report 2013;62."},{"key":"2025090510305356000_46.2.139.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2012.05.017"},{"key":"2025090510305356000_46.2.139.11","unstructured":"Janssen Pharmaceuticals Inc . LABEL: ORTHO TRI CYCLEN LO- norgestimate and ethinyl estradiol, 2019. Available: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=a1cfdb57-58fd-4fbd-ae18-571c97bff2cd [Accessed 1 Sep 2019]."},{"key":"2025090510305356000_46.2.139.12","unstructured":"Bayer HealthCare Pharmaceuticals Inc . LABEL: YASMIN- drospirenone and ethinyl estradiol, 2017. Available: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=d7ea6a60-5a56-4f81-b206-9b27b7e58875 [Accessed 1 Sep 2019]."},{"key":"2025090510305356000_46.2.139.13","unstructured":"Bayer HealthCare Pharmaceuticals Inc . LABEL: YAZ- drospirenone and ethinyl estradiol, 2017. Available: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=065f33e4-b587-4e66-b896-ca9ab7b7c876 [Accessed 1 Sep 2019]."},{"key":"2025090510305356000_46.2.139.14","unstructured":"Janssen Pharmaceuticals Inc . LABEL: ORTHO TRI CYCLEN- norgestimate and ethinyl estradiol kit\/ORTHO CYCLEN- norgestimate and ethinyl estradiol kit, 2019. Available: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=384e7a40-dcbd-4908-bf5e-65abc9932973 [Accessed 1 Sep 2019]."},{"key":"2025090510305356000_46.2.139.15","unstructured":"Bayer HealthCare Pharmaceuticals Inc . Drug label: MIRENA- levonorgestrel intrauterine device, 2017. Available: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=dcbd6aa2-b3fa-479a-a676-56ea742962fc [Accessed 1 Sep 2019]."},{"key":"2025090510305356000_46.2.139.16","unstructured":"Pfizer Inc . LABEL: DEPO-PROVERA- medroxyprogesterone acetate injection, suspension, 2019. Available: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=199cf13e-0859-4a73-9b45-e700d0cd1049 [Accessed 1 Sep 2019]."},{"key":"2025090510305356000_46.2.139.17","unstructured":"Merck & Co Inc . LABEL: NUVARING- etonogestrel and ethinyl estradiol insert, extended release, 2019. Available: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=017343fb-86c4-45ab-9c47-52cc5b9f3a02 [Accessed 1 Sep 2019]."},{"key":"2025090510305356000_46.2.139.18","unstructured":"Janssen Pharmaceuticals Inc . Ortho Evra\u00ae (norelgestromin\/ethinyl estradiol transdermal system), 2017. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021180s048lbl.pdf [Accessed 1 Sep 2019]."},{"key":"2025090510305356000_46.2.139.19","first-page":"81","article-title":"Effectiveness of an oral contraceptive","volume":"130","author":"Pincus","year":"1959","journal-title":"Source Sci New Ser"},{"key":"2025090510305356000_46.2.139.20","unstructured":"U.S. Food and Drug Administration . AndroGel 1% Prescribing Information, 2019. Available: www.fda.gov\/medwatch [Accessed 7 May 2019]."},{"key":"2025090510305356000_46.2.139.21","first-page":"130","article-title":"Adverse effects of hormonal contraception","volume":"8","author":"Sabatini","year":"2011","journal-title":"Endokrinol"},{"key":"2025090510305356000_46.2.139.22","doi-asserted-by":"crossref","unstructured":"Skovlund CW , M\u00f8rch LS , Kessing LV , et al . Association of hormonal contraception with depression. JAMA Psychiatry 2016;73.doi:10.1001\/jamapsychiatry.2016.2387","DOI":"10.1001\/jamapsychiatry.2016.2387"},{"key":"2025090510305356000_46.2.139.23","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/0024363918816683","article-title":"Systematic review of hormonal contraception and risk of venous thrombosis","volume":"85","author":"Keenan","year":"2018","journal-title":"Linacre Q"},{"key":"2025090510305356000_46.2.139.24","first-page":"177","article-title":"Women\u2019s trials: the approval of the first oral contraceptive pill in the United States and Great Britain","volume":"57","author":"White Junod","year":"2002","journal-title":"J Hist Med Allied Sci"},{"key":"2025090510305356000_46.2.139.25","doi-asserted-by":"crossref","DOI":"10.1186\/s12884-015-0505-4","article-title":"Impact of unintended pregnancy on maternal mental health: a causal analysis using follow up data of the panel study on Korean children (PSKC)","volume":"15","author":"Bahk","year":"2015","journal-title":"BMC Pregnancy Childbirth"},{"key":"2025090510305356000_46.2.139.26","first-page":"621","article-title":"Contraception choices in women with underlying medical conditions","volume":"82","author":"Bonnema","year":"2010","journal-title":"Am Fam Physician"},{"key":"2025090510305356000_46.2.139.27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jad.2016.07.044","article-title":"Prevalence of paternal depression in pregnancy and the postpartum: an updated meta-analysis","volume":"206","author":"Cameron","year":"2016","journal-title":"J Affect Disord"},{"key":"2025090510305356000_46.2.139.28","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/jclp.22630","article-title":"Spouses' prenatal autonomous motivation to have a child and postpartum depression symptoms","volume":"74","author":"Reut","year":"2018","journal-title":"J Clin Psychol"},{"key":"2025090510305356000_46.2.139.29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0950-3552(96)80059-9","article-title":"Male contraception","volume":"10","author":"Wu","year":"1996","journal-title":"Baillieres Clin Obstet Gynaecol"},{"key":"2025090510305356000_46.2.139.30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021997"}],"container-title":["BMJ Sexual &amp; Reproductive Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjsrh-2018-200206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T17:51:35Z","timestamp":1757094695000},"score":1,"resource":{"primary":{"URL":"https:\/\/jfprhc.bmj.com\/lookup\/doi\/10.1136\/bmjsrh-2018-200206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,4,17]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1136\/bmjsrh-2018-200206"],"URL":"https:\/\/doi.org\/10.1136\/bmjsrh-2018-200206","relation":{},"ISSN":["2515-1991","2515-2009"],"issn-type":[{"value":"2515-1991","type":"print"},{"value":"2515-2009","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]}}}